Grand View Research valued the global probiotic market at $65.5 billion in 2024, yet gastroenterologist Dr. Patricia Raymond (Eastern Virginia Medical School) estimates fewer than a dozen strains have rigorous clinical backing. The fundamental principle: probiotics are strain-specific. Recommending probiotics by genus without specifying the strain is like recommending medication by drug class without specifying the drug.
The strongest evidence comes from a 2023 Cochrane review (k=42, n=11,305) led by Dr. Joshua Goldenberg: for antibiotic-associated diarrhea, Saccharomyces boulardii and Lactobacillus rhamnosus GG show a 37% relative risk reduction (NNT=13). For IBS, the AGA's 2020 conditional recommendation singles out Bifidobacterium infantis 35624, based on Dr. Eamonn Quigley's (Houston Methodist) three randomized trials showing significant improvement in global IBS symptoms versus placebo.
For general gut health in healthy adults, the evidence is surprisingly thin. Dr. Eran Elinav (Weizmann Institute) published a landmark Cell paper (2018, n=25) showing that commercial probiotics colonized some guts but not others, with no predictable benefit, and in some participants actually delayed microbiome recovery after antibiotics.
CFU counts on labels are largely meaningless without context. A 2023 ConsumerLab analysis tested 56 probiotic products and found 15% contained fewer viable organisms than claimed. What matters: whether the strains have evidence for your condition, whether the CFU count matches the relevant trial dosing, and whether the product carries USP or NSF third-party verification.
Refrigeration requirements depend on strain and formulation. Dr. Mary Ellen Sanders, executive science officer of the International Scientific Association for Probiotics and Prebiotics (ISAPP), notes that storage above recommended temperatures can reduce viability by 90% or more, and shelf-stable claims require validated stability data.
Practical recommendations: for antibiotic-associated diarrhea prevention, start S. boulardii (250 mg twice daily) on day one of antibiotics and continue one week after completion. For IBS, trial B. infantis 35624 (1×10⁸ CFU daily) for four to eight weeks. For general health, Dr. Justin Sonnenburg (Stanford) argues the better investment is dietary fiber diversity: his 2021 Cell paper (n=36) showed a high-fiber diet increased microbiome diversity more than any probiotic supplement tested.